Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, K.
Right arrow Articles by Bunn, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, K.
Right arrow Articles by Bunn, P. A., Jr.
Clinical Cancer Research Vol. 6, 3474-3479, September 2000
© 2000 American Association for Cancer Research

Clinical Trials

A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer1

Karen Kelly2, Nadine Mikhaeel-Kamel, Zhaoxing Pan, James Murphy, Sheila Prindiville and Paul A. Bunn, Jr.

Division of Medical Oncology [K. K., P. A. B., N. M.], Lung Cancer Program, [K. K., S. P., P. A. B.], and Department of Preventive Medicine and Biostatistics [Z. P., J. M.], University of Colorado Cancer Center, Denver, Colorado 80262

Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. J. Edelman, J. I. Clark, K. Chansky, K. Albain, N. Bhoopalam, G. R. Weiss, J. K. Giguere, K. Kelly, J. Crowley, and D. R. Gandara
Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel
Clin. Cancer Res., August 1, 2004; 10(15): 5022 - 5026.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Spira and D. S. Ettinger
Multidisciplinary Management of Lung Cancer
N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. M. Mauer, R. H. Ansari, P. C. Hoffman, S. A. Krauss, D. Taber, S. A. Tembe, G. T. Gabrys, T. Cotter, L. P. Schumm, L. Szeto, et al.
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer
Ann. Onc., May 1, 2003; 14(5): 722 - 728.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.